Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05245682

Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer

Locally Advanced Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:
Early-Phase Open-label Study of Tolinapant and Radiation in Cisplatin-Ineligible Patients With Previously Untreated, Locally Advanced Head and Neck Cancer

Clinical Trial Summary

This early-phase trial tests the safety and side effects of a tolinapant given together with radiation therapy in treating patients with head and neck cancer for which the patient has not received treatment in the past (previously untreated), has spread to nearby tissue or lymph nodes (locally advanced) and cannot receive cisplatin (cisplatin-ineligible). Tolinapant may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tolinapant and radiation therapy may kill more tumor cells.

Clinical Trial Description

Primary Objective: To evaluate the safety and tolerability of the recommended phase 2 dose (RP2D) of tolinapant when given in combination with radiation. Secondary Objectives: To assess preliminary efficacy of the combination of tolinapant and radiation in cisplatin ineligible patients with head and neck cancer as determined by locoregional control, two year progression-free survival (PFS), and two-year overall survival (OS). Exploratory Objective: To compare immune cell infiltrates following the first cycle of tolinapant + radiation, compared with baseline biopsy tissue and peripheral blood. TERTIARY/EXPLORATORY OBJECTIVES: I. To assess the effects of the combination of tolinapant + radiation on immune cells in blood and tumor. II. To assess the association between immune responses and FADD expression in tumors. OUTLINE: Patients undergo standard of care radiation therapy for a total of 35 fractions over 6-7 weeks and receive tolinapant orally (PO) daily for 7 days during weeks 1, 3, 5, and 7 of radiation therapy in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up 1, 3, 6, 12, and 24 months. ;

Study Design

Related Conditions & MeSH terms

  • Carcinoma
  • Carcinoma, Squamous Cell
  • Head and Neck Carcinoma of Unknown Primary
  • Head and Neck Neoplasms
  • Locally Advanced Head and Neck Squamous Cell Carcinoma
  • Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
  • Locally Advanced Laryngeal Squamous Cell Carcinoma
  • Locally Advanced Oropharyngeal Squamous Cell Carcinoma
  • Squamous Cell Carcinoma of Head and Neck
Clinical Trial Details
NCT number NCT05245682
Study type Interventional
Source Emory University
Contact Nicole C Schmitt, MD
Phone 404-778-1900
Email nicole.cherie.schmitt@emory.edu
Status Recruiting
Phase Early Phase 1
Start date February 17, 2022
Completion date October 21, 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT03426657 - Radiotherapy With Double Checkpoint Blockade of Locally Advanced HNSCC Phase 2
Recruiting NCT05172245 - Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer Phase 1
Completed NCT04949503 - A Real-world Study of the Efficacy and Safety of Nimotuzumab in Combination With Chemoradiotherapy for LASCCHN
Completed NCT04870840 - Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer Phase 1
Completed NCT04541355 - Sodium Thiosulfate in Preventing Ototoxicity for Squamous Cell Cancer Patients Undergoing Chemoradiation With Cisplatin Phase 2
Recruiting NCT03649048 - Low-Dose Weekly vs High-Dose Cisplatin N/A
Recruiting NCT05724602 - Radiotherapy Plus Xevinapant in Older Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05773079 - Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Not yet recruiting NCT05861557 - Neoadjuvant Radiotherapy Combined With Toripalimab for Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT05527782 - Induction Modified TPF Followed by Concurrent Chemoradiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1
Recruiting NCT05376553 - Study of Cemiplimab - TP Induction Chemotherapy in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Phase 1
Withdrawn NCT03875053 - Home Sleep Apnea Machine in Evaluating Obstructive Sleep Apnea in Patients With Stage III-IV Head and Neck Cancer N/A
Recruiting NCT04892173 - NBTXR3 With or Without Cetuximab in LA-HNSCC Phase 3
Withdrawn NCT05743270 - Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN Phase 2
Recruiting NCT06240689 - A Prospective Randomized Controlled Study of Immune Checkpoint Maintenance Therapy After Radiotherapy and Chemotherapy for Locally Advanced Head and Neck Tumors Based on Peripheral Blood CD8Tex Detection in Peripheral Blood Phase 2
Recruiting NCT04454489 - Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition Phase 2
Completed NCT01689194 - Efficacy Study of Genexol-PM and Cisplatin in Locally Advanced Head and Neck Cancer Phase 2
Recruiting NCT04947241 - Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC Phase 1
Recruiting NCT06129864 - A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy Phase 3